When was RenewalBio founded?

RenewalBio was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is RenewalBio located?

RenewalBio is headquartered in Rehovot, Israel.

Who is the current CEO of RenewalBio?

Omri Amirav-Drory of RenewalBio. They have also founded 2 companies.

How many employees does RenewalBio have?

As of Mar 31, 2026, the latest employee count at RenewalBio is 20.

Is RenewalBio a funded company?

RenewalBio is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 14, 2023.

When was the latest funding round of RenewalBio?

RenewalBio's latest funding was a $***** Seed round on Nov 11, 2025, with participation from 1 investor.

Where does RenewalBio rank among its competitors?

RenewalBio ranks 16th amongst 120 active competitors, of which 35 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Renewal Bio, which secured an undisclosed amount in Nov, 2025.

Who are the top competitors of RenewalBio?

RenewalBio's top competitors include Gameto, Sprout Pharmaceuticals and Ensoma. Among them, RenewalBio secured the most recent funding round in November, 2025.

RenewalBio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of a synthetic embryo and stem-cell therapeutic platform. It generates transplantable tissues and rejuvenates cells. It specializes in stem cell differentiation to produce transplantable human cells and tissues that address organ shortages. It tackles the global shortage of transplantable cells and organs through advanced stem cell technologies.

Website: www.renewal.bio
Email ID: *****@renewal.bio

Key Metrics

Founded Year

2022

Location

Rehovot, Israel

Stage

Seed

Latest Funding Round

Seed, Nov 11, 2025, $*****

Investors

YZi Labs & 1 more

Ranked

16^th among 120 active competitors

Employee Count

20 as on Mar 31, 2026

Similar Companies

Ensoma & 103 more

View RenewalBio's full profile

RenewalBio has raised funding over 2 rounds. Its first funding round was on Apr 14, 2023. Its latest funding round was a Seed round on Nov 11, 2025 for $*****. 1 investor participated in its latest round. RenewalBio has 2 institutional investors.

Here is the list of recent funding rounds of RenewalBio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 11, 2025	3019892	Seed	9669871	5251424	8882349	5322280
Apr 14, 2023	8684687	Seed	4158850	1148089	1004651	4174234

Access funding benchmarks and valuations. Sign up today!

View details of RenewalBio's funding rounds and investors

The founders of RenewalBio is Omri Amirav-Drory. Omri Amirav-Drory is the CEO of RenewalBio.

Here are the details of RenewalBio's key team members:

Omri Amirav-Drory: Co-Founder & CEO of RenewalBio and founder of 1 other company.
Contact Info: 1 email address

View details of RenewalBio's Founder profiles and Board Members

RenewalBio's employee count trend

RenewalBio has 20 employees as of Mar 26. Here is RenewalBio's employee count trend over the years:

Uncover RenewalBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RenewalBio include Gameto, Sprout Pharmaceuticals and Ensoma. Here is the list of Top 10 competitors of RenewalBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Gameto 2020, United States, Series C	Developer of therapeutics for the treatment of fertility and menopause	$127M	RA Capital Management, Insight Partners & 29 others	58/100
2nd	Sprout Pharmaceuticals 2011, Raleigh (United States), Acquired	Developer of drugs for hypoactive sexual desire disorder in women	$185M	New Ventures Funds, Lunsford Capital & 1 others	58/100
3rd	Ensoma 2019, Boston (United States), Series B	Developer of in vivo hematopoietic stem cell engineering for genomic medicine	$205M	5AM Ventures, Arix Bioscience & 18 others	58/100
4th	Rejoni 2020, Bedford (United States), Series B	Developer of therapeutics to treat women health conditions	$41.3M	Ascension Ventures, CHV & 6 others	56/100
5th	Granata Bio 2018, Duxbury (United States), Series A	Developer of therapeutics for women's health and infertility	$29M	Google Ventures, Alumni Ventures & 4 others	55/100
6th	Hope Medicine 2018, Shanghai (China), Series B	Developer of monoclonal antibodies for the treatment of multiple diseases	$56M	Sinovation Ventures, Qiming Venture Partners ... & 7 others	54/100
7th	Clade 2020, Cambridge (United States), Acquired	Developer of stem cell-derived therapies for cancer treatment	$87M	Syncona, Emerson Collective & 2 others	54/100
8th	OvaScience 2011, Waltham (United States), Public	Developer of new fertility treatments for women	$76.9M	RA Capital Management, Cycad Group & 5 others	53/100
9th	Immunis 2018, Irvine (United States), Series A	Developer of cell therapies for age-related and disease-related immune deficits	$55.4M	Remiges Ventures, Bold Capital Partners & 4 others	52/100
10th	Athersys 1995, Cleveland (United States), Public	Stem Cell Therapy for the treatment of cardiovascular disease areas	$74.4M	Cogene BioTech Ventures, Curran Partners, Inc. / ECI Group ... & 18 others	52/100
16th	RenewalBio 2022, Rehovot (Israel), Seed	Developer of a synthetic embryo and stem-cell therapeutic platform	-	Calm Ventures, YZi Labs	49/100